The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do Not Receive Chemoradiation-Reference-Cited by-同舟云学术

The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do Not Receive Chemoradiation

Published:2022-10-17 Issue:1 Volume:46 Page:14-21
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Amin Saber A.,Baine Michael J.,Rahman Ibur,Lin Chi

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference39 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system;Chen;Cancer,2014

3. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey;Morgensztern;J Thorac Oncol,2010

4. Immunotherapy in inoperable stage III non-small cell lung cancer: a review;Jain;Drugs Context,2019

5. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis;JNCI: Journal of the National Cancer Institute;2024-06-17

2. Enhancing safety and therapeutic efficacy: PD-1 inhibitor and recombinant human endostatin combination in advanced non-small cell lung cancer patients;American Journal of Translational Research;2024

3. Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC;Frontiers in Oncology;2023-03-23